Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge J Castillo

Showing results (251-260 of 343) with videos related to

Pageof 35
Sort By:
Blood|May 5, 2016
HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinibGuang Yang, Sara J Buhrlage, Li Tan, et al.
British Journal of Haematology|July 6, 2016
Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström MacroglobulinaemiaJorge J Castillo, Ramon Garcia-Sanz, Evdoxia Hatjiharissi, et al.
British Journal of Haematology|September 6, 2018
TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemiaJoshua N Gustine, Nicholas Tsakmaklis, Maria G Demos, et al.
Leukemia & Lymphoma|January 30, 2020
A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenström macroglobulinemiaJorge J Castillo, Gilad Itchaki, Joshua N Gustine, et al.
Blood Advances|January 15, 2020
Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomasXia Liu, Jiaji G Chen, Manit Munshi, et al.
Future Oncology (London, England)|July 29, 2024
Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trialAlessandra Tedeschi, Constantine S Tam, Roger G Owen, et al.
Blood|November 16, 2023
Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemiaJorge J Castillo, Andrew R Branagan, David Sermer, et al.
Blood Advances|October 2, 2019
<i>CXCR4</i><sup>S338X</sup> clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemiaJoshua N Gustine, Lian Xu, Nicholas Tsakmaklis, et al.
Blood Advances|December 3, 2024
Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemiaBenjamin M Heyman, Stephen S Opat, Björn E Wahlin, et al.
British Journal of Haematology|November 29, 2017
MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survivalSteven P Treon, Joshua Gustine, Lian Xu, et al.
Pageof 35

Showing results (251-260 of 343) with videos related to

Sort By:
Pageof 35
Blood|May 5, 2016
HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinibGuang Yang, Sara J Buhrlage, Li Tan, et al.
British Journal of Haematology|July 6, 2016
Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström MacroglobulinaemiaJorge J Castillo, Ramon Garcia-Sanz, Evdoxia Hatjiharissi, et al.
British Journal of Haematology|September 6, 2018
TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemiaJoshua N Gustine, Nicholas Tsakmaklis, Maria G Demos, et al.
Leukemia & Lymphoma|January 30, 2020
A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenström macroglobulinemiaJorge J Castillo, Gilad Itchaki, Joshua N Gustine, et al.
Blood Advances|January 15, 2020
Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomasXia Liu, Jiaji G Chen, Manit Munshi, et al.
Future Oncology (London, England)|July 29, 2024
Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trialAlessandra Tedeschi, Constantine S Tam, Roger G Owen, et al.
Blood|November 16, 2023
Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemiaJorge J Castillo, Andrew R Branagan, David Sermer, et al.
Blood Advances|October 2, 2019
<i>CXCR4</i><sup>S338X</sup> clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemiaJoshua N Gustine, Lian Xu, Nicholas Tsakmaklis, et al.
Blood Advances|December 3, 2024
Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemiaBenjamin M Heyman, Stephen S Opat, Björn E Wahlin, et al.
British Journal of Haematology|November 29, 2017
MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survivalSteven P Treon, Joshua Gustine, Lian Xu, et al.
Pageof 35